[1] |
Higueros E, Roe E, Granell E, et al. Sturge⁃Weber syndrome: a review[J]. Actas Dermosifiliogr, 2017,108(5):407⁃417. doi: 10.1016/j.ad.2016.09.022.
|
[2] |
Fjær R, Marciniak K, Sundnes O, et al. A novel somatic mutation in GNB2 provides new insights to the pathogenesis of Sturge⁃Weber syndrome[J]. Hum Mol Genet, 2021,30(21):1919⁃1931. doi: 10.1093/hmg/ddab144.
|
[3] |
Sánchez⁃Espino LF, Ivars M, Antoñanzas J, et al. Sturge⁃Weber syndrome: a review of pathophysiology, genetics, clinical features, and current management approache[J]. Appl Clin Genet, 2023,16:63⁃81. doi: 10.2147/TACG.S363685.
|
[4] |
Sudarsanam A, Ardern⁃Holmes SL. Sturge⁃Weber syndrome: from the past to the present[J]. Eur J Paediatr Neurol, 2014,18(3):257⁃266. doi: 10.1016/j.ejpn.2013.10.003.
|
[5] |
Zallmann M, Mackay MT, Leventer RJ, et al. Retrospective review of screening for Sturge⁃Weber syndrome with brain magnetic resonance imaging and electroencephalography in infants with high⁃risk port⁃wine stains[J]. Pediatr Dermatol, 2018,35(5):575⁃581. doi: 10.1111/pde.13598.
|
[6] |
Yeom S, Comi AM. Updates on Sturge⁃Weber syndrome[J]. Stroke, 2022,53(12):3769⁃3779. doi: 10.1161/STROKEAHA. 122.038585.
|
[7] |
Mantelli F, Bruscolini A, La Cava M, et al. Ocular manifestations of Sturge⁃Weber syndrome: pathogenesis, diagnosis, and management[J]. Clin Ophthalmol, 2016,10:871⁃878. doi: 10. 2147/OPTH.S101963.
|
[8] |
Sabeti S, Ball KL, Bhattacharya SK, et al. Consensus statement for the management and treatment of Sturge⁃Weber syndrome: neurology, neuroimaging, and ophthalmology recommendations[J]. Pediatr Neurol, 2021,121:59⁃66. doi: 10.1016/j.pediatrneurol. 2021.04.013.
|
[9] |
Sikakulya FK, Egesa WI, Kiyaka SM, et al. A neonate with Klippel⁃Trénaunay syndrome: a case report[J]. J Med Case Rep, 2021,15(1):447. doi: 10.1186/s13256⁃021⁃03029⁃4.
|
[10] |
Naganathan S, Tadi P. Klippel⁃Trenaunay⁃Weber syndrome[M/OL]. Treasure Island (FL): StatPearls Publishing, 2024[2024⁃04⁃12]. https://www.ncbi.nlm.nih.gov/books/NBK558989/.
|
[11] |
Bastarrika G, Redondo P, Sierra A, et al. New techniques for the evaluation and therapeutic planning of patients with Klippel⁃Trénaunay syndrome[J]. J Am Acad Dermatol, 2007,56(2):242⁃249. doi: 10.1016/j.jaad.2006.08.057.
|
[12] |
中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形的诊断及治疗指南(2019版)[J]. 组织工程与重建外科杂志, 2019,15(5):277⁃317. doi: 10.3969/j.issn.1673⁃0364. 2019.05.001.
|
[13] |
Zhai J, Zhong ME, Shen J, et al. Kyphoscoliosis with Klippel⁃Trenaunay syndrome: a case report and literature review[J]. BMC Musculoskelet Disord, 2019,20(1):10. doi: 10.1186/s12891⁃ 018⁃2393⁃z.
|
[14] |
Sandbank S, Molho⁃Pessach V, Farkas A, et al. Oral and topical sirolimus for vascular anomalies: a multicentre study and review[J]. Acta Derm Venereol, 2019,99(11):990⁃996. doi: 10.2340/00015555⁃3262.
|
[15] |
Canaud G, Lopez Gutierrez JC, Irvine AD, et al. Alpelisib for treatment of patients with PIK3CA⁃related overgrowth spectrum (PROS)[J]. Genet Med, 2023,25(12):100969. doi: 10.1016/j.gim.2023.100969.
|
[16] |
Banzic I, Brankovic M, Maksimović Ž, et al. Parkes Weber syndrome⁃diagnostic and management paradigms: a systematic review[J]. Phlebology, 2017,32(6):371⁃383. doi: 10.1177/0268355516664212.
|
[17] |
Flores Daboub JA, Grimmer JF, Frigerio A, et al. Parkes Weber syndrome associated with two somatic pathogenic variants in RASA1[J]. Cold Spring Harb Mol Case Stud, 2020,6(4):a005256. doi: 10.1101/mcs.a005256.
|
[18] |
Eng W, Sudduth CL, Konczyk DJ, et al. Parkes Weber syndrome with lymphedema caused by a somatic KRAS variant[J]. Cold Spring Harb Mol Case Stud, 2021,7(6):a006118. doi: 10.1101/mcs.a006118.
|
[19] |
Szeliga A, Spyt D, Maćków E, et al. Parkes Weber syndrome[J]. Journal of Education, Health and Sport, 2019,9(8):987⁃997. doi:10.5281/zenodo.3408576.
|
[20] |
Vidaurri⁃de la Cruz H, Tamayo⁃Sánchez L, Durán⁃McKinster C, et al. Phakomatosis pigmentovascularis ⅡA and ⅡB: clinical findings in 24 patients[J]. J Dermatol, 2003,30(5):381⁃388. doi: 10.1111/j.1346⁃8138.2003.tb00403.x.
|
[21] |
Torrelo A, Zambrano A, Happle R. Cutis marmorata telangiectatica congenita and extensive mongolian spots: type 5 phacomatosis pigmentovascularis[J]. Br J Dermatol, 2003,148(2):342⁃345. doi: 10.1046/j.1365⁃2133.2003.05118.x.
|
[22] |
Torchia D. Phacomatosis spilorosea versus phacomatosis melanorosea: a critical reappraisal of the worldwide literature with updated classification of phacomatosis pigmentovascularis[J]. Acta Dermatovenerologica Alpina, Pannonica, Et Adriatica, 2021, 30(1): 27⁃30. doi: 10.15570/actaapa.2021.6.
|
[23] |
Polubothu S, Bender N, Muthiah S, et al. PTPN11 mosaicism causes a spectrum of pigmentary and vascular neurocutaneous disorders and predisposes to melanoma[J]. J Invest Dermatol, 2023,143(6):1042⁃1051.e3. doi: 10.1016/j.jid.2022.09.661.
|
[24] |
李敏, 张守民, 尹光文, 等. 儿童色素血管性斑痣性错构瘤病10例分析[J]. 中国皮肤性病学杂志, 2018,32(6):654⁃657. doi: 10.13735/j.cjdv.1001⁃7089.201712083.
|
[25] |
Fageeh SM, Alhothali OS, Alharbi SF, et al. Diffuse capillary malformation with overgrowth (DCMO): a case report and literature review[J]. Cureus, 2023,15(3):e35776. doi: 10. 7759/cureus.35776.
|
[26] |
Lee MS, Liang MG, Mulliken JB. Diffuse capillary malformation with overgrowth: a clinical subtype of vascular anomalies with hypertrophy[J]. J Am Acad Dermatol, 2013,69(4):589⁃594. doi: 10.1016/j.jaad.2013.05.030.
|
[27] |
Gonzalez ME, Burk CJ, Barbouth DS, et al. Macrocephaly⁃capillary malformation: a report of three cases and review of the literature[J]. Pediatr Dermatol, 2009,26(3):342⁃346. doi: 10. 1111/j.1525⁃1470.2009.00924.x.
|
[28] |
Mirzaa G, Dodge NN, Glass I, et al. Megalencephaly and perisylvian polymicrogyria with postaxial polydactyly and hydrocephalus: a rare brain malformation syndrome associated with mental retardation and seizures[J]. Neuropediatrics, 2004,35(6):353⁃359. doi: 10.1055/s⁃2004⁃830497.
|
[29] |
Alamar M, Candela S, Flor⁃Goikoetxea A, et al. Megalencephaly⁃capillary malformation syndrome and associated hydrocephalus: treatment options and revision of the literature[J]. Childs Nerv Syst, 2021,37(8):2441⁃2449. doi: 10.1007/s00381⁃021⁃05222⁃8.
|
[30] |
Postma JK, Zambonin JL, Khouj E, et al. Further clinical delineation of microcephaly⁃capillary malformation syndrome[J]. Am J Med Genet A, 2022,188(11):3350⁃3357. doi: 10. 1002/ajmg.a.62936.
|
[31] |
唐金玲, 李珂瑶, 罗勇奇, 等. CLOVES综合征1例[J]. 中华皮肤科杂志, 2023,56(3):259⁃261. doi: 10.35541/cjd.20201198.
|
[32] |
Garreta Fontelles G, Pardo Pastor J, Grande Moreillo C. Alpelisib to treat CLOVES syndrome, a member of the PIK3CA⁃related overgrowth syndrome spectrum[J]. Br J Clin Pharmacol, 2022,88(8):3891⁃3895. doi: 10.1111/bcp.15270.
|
[33] |
Biesecker LG. Proteus syndrome[M]//John CC, Agatino B, David V, et al. Cassidy and Allanson′s management of genetic syndromes. 4th ed. New York: Wiley International Publishing, 2021: 763⁃773. doi: 10.1002/9781119432692.ch47.
|
[34] |
Panteliadis CP, Friedrich RE. Proteus syndrome[M]//Panteliadis CP, Benjamin R, Hagel C. Neurocutaneous disorders: a clinical, diagnostic and therapeutic approach. Cham: Springer International Publishing, 2022: 247⁃253. doi: 10.1007/978⁃3⁃030⁃87893⁃1_22.
|
[35] |
Manor J, Lalani SR. Overgrowth syndromes⁃evaluation, diagnosis, and management[J]. Front Pediatr, 2020,8:574857. doi: 10. 3389/fped.2020.574857.
|
[36] |
Wang MX, Kamel S, Elsayes KM, et al. Vascular anomaly syndromes in the ISSVA classification system: imaging findings and role of interventional radiology in management[J]. Radiographics, 2022,42(6):1598⁃1620. doi: 10.1148/rg. 210234.
|
[37] |
Lamberg O, Strome A, Pedersen E, et al. CLAPO syndrome[J]. Eur J Pediatr Dermatol, 2022,32(3):147⁃150. doi:10.26326/2281⁃9649.32.3.2384.
|
[38] |
González⁃Hermosa MR, Guerra E, Tuduri I, et al. CLAPO syndrome: effective response to treatment with oral rapamycin[J]. Dermatol Ther, 2019,32(4):e12991. doi: 10.1111/dth. 12991.
|
[39] |
Lin N, Zhao X. Unique Cobb syndrome with Kaposi hemangioendothelioma/tufted angioma as dominant phenotype: a case report[J]. World J Pediatr Surg, 2023,6(4):e000695. doi: 10.1136/wjps⁃2023⁃000695.
|
[40] |
Clark MT, Brooks EL, Chong W, et al. Cobb syndrome: a case report and systematic review of the literature[J]. Pediatr Neurol, 2008,39(6):423⁃425. doi: 10.1016/j.pediatrneurol.2008.08.001.
|
[41] |
张蕊蕊, 李秀云, 储照虎. Cobb综合征一例 [J] . 中华神经科杂志, 2021,54(4):388⁃391. doi: 10.3760/cma.j.cn113694⁃2020 0723⁃00564.
|
[42] |
Wang KH, Kupa J, Duffy KA, et al. Diagnosis and management of Beckwith⁃Wiedemann syndrome[J]. Front Pediatr, 2019,7:562. doi: 10.3389/fped.2019.00562.
|
[43] |
Al⁃Samkari H .Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care[J].Blood, 2020,137(7):888⁃895. doi: 10.1182/blood.2020008739.
|
[44] |
Bui TNPT, Corap A, Bygum A. Cutis marmorata telangiectatica congenita: a literature review[J]. Orphanet J Rare Dis, 2019,14(1):283. doi: 10.1186/s13023⁃019⁃1229⁃8.
|
[45] |
Russell BE, Kianmahd RR, Munster C, et al. Clinical findings in 39 individuals with Bohring⁃Opitz syndrome from a global patient⁃driven registry with implications for tumor surveillance and recurrence risk[J]. Am J Med Genet A, 2023,191(4):1050⁃1058. doi: 10.1002/ajmg.a.63125.
|